Amarin Corp Plc (AMRN)

[AVII77]

One placebo-controlled study of around 300 subjects that tried a dose of 4g/d n-3 failed, and actually showed a trend towards increased MACE risk in fish oil group:

ajcn.nutrition.org/content/74/1/50.long

Interesting study using 4g/d lovaza.

A similar study was reported recently. It too was in high risk patients who recently had a MI. But it used EPA only (1.8g/day).

Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study

Results were quite a bit different from the Lovaza study. RRR was 58%.

Any thought on why the Lovaza study you cited would show harm and this EPA study showed dramatic benefit? What was different between the two otherwise similar studies?